Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. (APRE) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
apre · stock forecast · 8 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 8 Wall Street analysts in the past 3 months
Buy
8 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $0.73
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $0.70 | ↓ 5.00% |
1-day model range: $0.68–$0.71. Peak: $0.71 (-5.00%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | — | -50.0% |
| 2028 | — | -62.5% |
| 2029 | — | -67.2% |
| 2030 | — | -69.2% |
| 2031 | — | -70.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · APRE · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-14 | Wedbush | Maintains | Outperform→Outperform |
| 2026-03-31 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-03-31 | Wedbush | Maintains | Outperform→Outperform |
| 2026-02-10 | Wedbush | Maintains | Outperform→Outperform |
| 2026-01-29 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-12-18 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-01-15 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-12-17 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-11-18 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-10-24 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Aprea Therapeutics, Inc. (APRE) stock. Of the recent 39 rating actions, 0 were upgrades and 4 were downgrades. 8 analysts currently cover APRE.
Analyst Recommendation Trends
APRE analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$1M
↓ 73.4% YoY
Revenue Next Year
$2M
↑ 111.5% YoY
EPS This Year
$-0.68
EPS Next Year
$-0.65
↓ 4.4% YoY
EPS ForecastReported vs Estimated
Analysts forecast APRE EPS of $-0.68 for the current fiscal year, based on estimates from 3 analysts. The APRE revenue forecast is $1M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The APRE stock forecast is supported by two independent data sources: analyst consensus ratings from 8 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus APRE price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The APRE short-term stock prediction for tomorrow is $0.70 (-5.00%). The APRE stock prediction for 2030 projects a range of $0–$0.
Aprea Therapeutics, Inc. trades on NASDAQ under the ticker APRE. The APRE stock outlook for 2027 is broadly positive, supported by a Buy consensus among 50% of covering analysts.
Frequently asked questions
APRE forecast · 8 questionsAccording to 8 Wall Street analysts, the average 12-month APRE price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $0.73.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.